Morphogen-IX

Morphogen-IX is a drug discovery company founded by Index Ventures in 2015 to develop bone morphogenetic proteins as a new therapy for treating pulmonary arterial hypertension (PAH). The company operates on a semi-virtual model, with its core based in Cambridge, UK. The founders of the company are experts in the fields of PAH and BMP. The team is supported by experienced drug discovery professionals to oversee outsourced development programs.